Comparative safety and effectiveness of warfarin, dabigatran, and rivaroxaban among Japanese patients with non-valvular atrial fibrillation (NVAF) and concomitant coronary artery disease (CAD) (1160.0308)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS41345
• Study ID:
  103354
• Official title and acronym:
  Comparative safety and effectiveness of warfarin, dabigatran, and rivaroxaban among Japanese patients with non-valvular atrial fibrillation (NVAF) and concomitant coronary artery disease (CAD) (1160.0308)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  No information provided.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:01/05/2022

Actual:01/01/2022

Study start date

Planned:01/05/2022

Actual:17/03/2022

Data analysis start date

Planned:30/11/2021

Date of final study report

Planned:31/12/2022

Actual:28/11/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim (China) Investment Co., Ltd

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable